Short Term Price Target on Baxter International (BAX)

Baxter International (NYSE:BAX) : The most positive equity analysts on Baxter International (NYSE:BAX) expects the shares to touch $60, whereas, the least positive believes that the stock will trade at $46 in the short term. The company is covered by 6 Wall Street Brokerage Firms. The average price target for shares are $48.83 with an expected fluctuation of $5.49 from the mean.

Baxter International Inc. has dropped 1.61% in the last five trading days, however, the shares have posted positive gains of 4.36% in the last 4 weeks. Baxter International Inc. is up 8.79% in the last 3-month period. Year-to-Date the stock performance stands at 19.23%.

Baxter International (NYSE:BAX) : 1 brokerage houses believe that Baxter International (NYSE:BAX) is a Strong Buy at current levels. 9 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Baxter International (NYSE:BAX). Zacks Investment Research suggests a Hold with a rank of 3. 1 others believe that the stock has run up ahead of its fundamentals and advise a Strong Sell on the stock.The median of all the 11 Wall Street Analysts endorse the stock as a Hold with a rating of 2.94.

Baxter International (NYSE:BAX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $44.99 and $44.76 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $45.24. The buying momentum continued till the end and the stock did not give up its gains. It closed at $45.22, notching a gain of 0.89% for the day. The total traded volume was 5,242,502 . The stock had closed at $44.82 on the previous day.

In an insider trading activity, Almeida Jose E, CEO of Baxter International Inc, executed a transaction worth $499,790 on May 23, 2016. A total of 11,691 shares were purchased at an average price of $42.75. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.

Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.